Orr, Miranda E. http://orcid.org/0000-0002-0418-2724
Kotkowski, Eithan
Ramirez, Paulino
Bair-Kelps, Darcy
Liu, Qianqian
Brenner, Charles
Schmidt, Mark S.
Fox, Peter T.
Larbi, Anis
Tan, Crystal
Wong, Glenn
Gelfond, Jonathan
Frost, Bess
Espinoza, Sara
Musi, Nicolas
Powers, Becky
Funding for this research was provided by:
South Texas Medical Scientist Training Program (T32GM113898)
National Institute of Mental Health and Neurosciences (R01MH074457-11S1, R01MH074457)
National Center for Advancing Translational Sciences (TL1TR002647)
National Institute on Aging (P30AG044271)
Article History
Received: 4 September 2023
Accepted: 24 October 2023
First Online: 23 November 2023
Declarations
:
: ChromaDex Inc. provided the investigators with NR and placebo. Charles Brenner, a co-author, is an inventor of intellectual property on uses of nicotinamide riboside. He serves as Chief Scientific Advisor of ChromaDex and owns ChromaDex stock. Dr. Brenner’s contributions included data interpretation regarding NAD+ metabolites and manuscript editing. He was not involved in study design or execution. Dr. Orr reports a grant from US Department of Veterans Affairs during the conduct of the study. In addition, Dr. Orr has a patent biosignature and therapeutic approach for neuronal senescence pending outside the scope of this work. No other co-authors have COIs to declare.
: The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.